NCT05297136

Brief Summary

Distal pancreatectomy (DP) with or without splenectomy is commonly indicated for pancreatic body or tail lesions. Postoperative pancreatic fistula (POPF) remains the commonest complication after DP. A pre-operatively placed pancreatic stent across papilla can decrease the pressure gradient between pancreatic duct and duodenum. Therefore, the pancreatic juice flow is redirected from the pancreatic transection plane and leakage from pancreatic stump is much reduced. This study aims to evaluate whether pre-operatively placed pancreatic stent can prevent POPF by a randomized controlled trial.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
1mo left

Started Mar 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Mar 2022May 2026

First Submitted

Initial submission to the registry

March 3, 2022

Completed
18 days until next milestone

Study Start

First participant enrolled

March 21, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 28, 2022

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2026

Expected
Last Updated

March 28, 2022

Status Verified

March 1, 2022

Enrollment Period

4 years

First QC Date

March 3, 2022

Last Update Submit

March 22, 2022

Conditions

Keywords

Distal PancreatectomyPancreatic Fistula

Outcome Measures

Primary Outcomes (1)

  • Number of participants with postoperative pancreatic fistula

    The number of participants developing post-operative pancreatic fistula, which is defined as drain fluid amylase more than 3 times the upper limit of the normal value of serum amylase on or after postoperative day 3

    Day 3 after operation

Secondary Outcomes (4)

  • Number of participants developing post-operative morbidity

    90 days

  • Number of participants developing post-operative mortality

    90 days

  • Total length of hospital stay of participants

    90 days after endoscopy and operation

  • Number of participants developing complications related to Endoscopic Retrograde Cholangiography

    14 days after endoscopy

Study Arms (2)

Pre-op Stenting

EXPERIMENTAL

Pre-operative pancreatic stent inserted by Endoscopic Retrograde Cholangiography, followed by distal pancreatectomy

Procedure: Pancreatic Stenting

Surgery alone

ACTIVE COMPARATOR

Distal pancreatectomy alone

Procedure: No Stent

Interventions

Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy

Pre-op Stenting
No StentPROCEDURE

No preoperative stenting with distal pancreatectomy alone

Surgery alone

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years
  • Elective distal pancreatectomy for primary pancreatic pathology

You may not qualify if:

  • Informed consent not available
  • Emergency distal pancreatectomy
  • Presence of pancreatic duct stricture
  • Presence of altered anatomy that precludes safe Endoscopic Retrograde Cholangiography (e.g. previous Billroth II gastrectomy)
  • History of severe pancreatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Pancreatic Fistula

Condition Hierarchy (Ancestors)

Digestive System FistulaDigestive System DiseasesPancreatic DiseasesFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Kit Fai Lee, MBBS

    Clinical Associate Professor (honorary)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kit Fai Lee, MBBS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor (honorary)

Study Record Dates

First Submitted

March 3, 2022

First Posted

March 28, 2022

Study Start

March 21, 2022

Primary Completion

March 20, 2026

Study Completion (Estimated)

May 20, 2026

Last Updated

March 28, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations